SELENOW and Alzheimer disease: As shown in Supplementary Fig. 5b, no significant change of MDA levels had been detected, while in Fig. 8b, SELENOW overexpression significantly reduced the levels of Iba-1 and upregulated the levels of Oligo2 in 3×Tg AD mice.